Behavioral Interventions for Individuals Dually Diagnosed with a Severe Mental Illness and a Substance Use Disorder

Current Addiction Reports

Volumn 1, Issue 4, 2014, Pages 243-250

  Bradizza, Clara M ^a   Stasiewicz, Paul R ^a   Dermen, Kurt H ^a  

^a RESEARCH INSTITUTE ON ADDICTIONS   (United States)

Author keywords

Behavioral interventions; Cognitive behavioral therapy; Contingency management; Dual diagnosis; Motivational interviewing; Schizophrenia

Indexed keywords

EID: 84964462122     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-014-0032-9     Document Type: Review

References (49)

1. Apodaca TR, Longabaugh R. Mechanisms of change in motivational interviewing: a review and preliminary evaluation of the evidence. Addiction. 2009;104(5):705–15. doi:10.1111/j.1360-0443.2009.02527.x.
2. Baker AL, Hiles SA, Thornton LK, Hides L, Lubman DI. A systematic review of psychological interventions for excessive alcohol consumption among people with psychotic disorders. Acta Psychiatr Scand. 2012;126(4):243–55. doi:10.1111/j.1600-0447.2012.01885.x.
3. Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, et al. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med. 2014;44(13):2749–61. doi:10.1017/S0033291714000208.
4. Bernard PP, Esseul EC, Raymond L, Dandonneau L, Xambo JJ, Carayol MS, et al. Counseling and exercise intervention for smoking reduction in patients with schizophrenia: a feasibility study. Arch Psychiatr Nurs. 2013;27(1):23–31. doi:10.1016/j.apnu.2012.07.001.
5. Bonsack C, Gibellini Manetti S, Favrod J, Montagrin Y, Besson J, Bovet P, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychother Psychosom. 2011;80(5):287–97. doi:10.1159/000323466.
6. Carey MP, Carey KB, Meisler AW. Psychiatric symptoms in mentally ill chemical abusers. J Nerv Ment Dis. 1991;179(3):136–8.
7. Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE. An open trial of relapse prevention therapy for smokers with schizophrenia. J Dual Diagn. 2013;9(1):87–93.
8. Cleary M, Hunt G, Matheson S, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2008;23(1):CD001088.
9. De Witte NA, Crunelle CL, Sabbe B, Moggi F, Dom G. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res. 2014;20(3):105–14. doi:10.1159/000355267.
10. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J. 2004;27(4):360–74.
11. Drake RE, Mueser KT, Torrey WC, Miller AL, Lehman AF, Bond GR, et al. Evidence-based treatment of schizophrenia. Curr Psychiatr Rep. 2000;2(5):393–7.
12. Drake RE, Osher FC, Wallach MA. Alcohol-use and abuse in schizophrenia - a prospective community study. J Nerv Ment Dis. 1989;177(7):408–14. doi:10.1097/00005053-198907000-00004.
13. Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hosp Community Psychiatry. 1989;40(10):1041–6.
14. Goldie CL, Masuhara EJ, Heah T, Okoli C, Johnson JL. Outpatient tobacco dependence treatment for individuals with severe mental illness: the butt out program outcomes. Can J Community Mental Health. 2012;31(1):87–98.
15. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J. 2003;39(3):189–202.
16. Handmaker N, Packard M, Conforti K. Motivational Interviewing in the treatment of dual disorders. In: W. R. R. Miller, S. (Ed.), Motivational Interviewing: Preparing People for Change (2nd ed., pp. 362-376). New York: Guilford; 2002.
17. Higgins ST, Petry NM. Contingency management. Incentives for sobriety. Alcohol Res Health J Natl Inst Alcohol Abus Alcohol. 1999;23(2):122–7.
18. Higgins ST, Silverman K, Heil SH. Contingency management in substance abuse treatment. New York: Guilford Press; 2008.
19. Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med. 2013;43(7):1499–510. doi:10.1017/S0033291712002255.
20. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2013;10:CD001088. doi:10.1002/14651858.CD001088.pub3. Sytematic review of psychosocial treatments, including behavioral interventions, for substance abuse among SMI individuals that accounts for number and quality of studies in drawing conclusions regarding efficacy.
21. Kadden R, Carroll KM, Donovan D, Cooney N, Monti PM, Abrams DB, et al. Cognitive-behavioral coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. (DHHS Publication No. 94-3724). Rockville: NIAAA; 1994.
22. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54(4):313–21.
23. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res. 2013;143(1):138–42. doi:10.1016/j.schres.2012.10.018.
24. Marlatt A, Gordon J, editors. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: The Guildford Press; 1985.
25. Martin T, Christopher PJ, Houck JM, Moyers TB. The structure of client language and drinking outcomes in project match. Psychol Addict Behav. 2011;25(3):439–45. doi:10.1037/a0023129.
26. Martino S. Contemplating the use of motivational interviewing with patients who have schizophrenia and substance use disorders. Clin Psychol Sci Pract. 2007;14(1):58–63. doi:10.1111/j.1468-2850.2007.00062.x.
27. Martino S, Moyers TB. Motivational interviewing with dually diagnosed patients. In: Arkowitz H, Westra HA, Miller WR, Rollnick S, editors. Motivational interviewing in the treatment of psychological problems. New York: Guilford; 2008. p. 277–303.
28. McDonell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatr. 2013;170(1):94–101. doi:10.1176/appi.ajp.2012.11121831. Randomized controlled trial of CM demonstrating some success in reducing stimulant abuse during both 3-month treatment and a 3-month follow-up.
29. Miller WR, Rollnick S. Motivational interviewing: helping people change. 3rd ed. New York: Guilford Press; 2013.
30. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational enhancement therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville: U. S. Department of Health and Human Services; 1994.
31. Miller WR, Zweben J, Johnson WR. Evidence-based treatment: why, what, where, when, and how? J Subst Abus Treat. 2005;29(4):267–76. doi:10.1016/j.jsat.2005.08.003.
32. Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res. 2011;17(3):154–63. doi:10.1159/000324480.
33. Moyers TB, Houck J. Combining motivational interviewing with cognitive-behavioral treatments for substance abuse: lessons from the COMBINE research project. Cogn Behav Pract. 2011;18(1):38–45.
34. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, et al. Prevalence of substance abuse in schizophrenia - demographic and clinical correlates. Schizophr Bull. 1990;16(1):31–56.
35. Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006;63(2):201–8. doi:10.1001/archpsyc.63.2.201.
36. Petry NM, Alessi SM, Rash CJ. A randomized study of contingency management in cocaine-dependent patients with severe and persistent mental health disorders. Drug Alcohol Depend. 2013;130(1–3):234–7. doi:10.1016/j.drugalcdep.2012.10.017.
37. Petry NM, Roll JM. Amount of earnings during prize contingency management treatment is associated with posttreatment abstinence outcomes. Exp Clin Psychopharmacol. 2011;19(6):445–50. doi:10.1037/a0024261.
38. Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction. 2004;99(3):349–60.
39. Prochaska JO, Johnson S, Lee P. The transtheoretical model of behavior change. In: Shumaker SA, Ockene JK, Riekert KA, editors. The handbook of health behavior change. 3rd ed. New York: Springer Publishing Co.; 2009. p. 59–83.
40. Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav. 2013;38(9):2455–62. doi:10.1016/j.addbeh.2013.03.018.
41. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150(1):42–50. doi:10.1016/j.schres.2013.07.009.
42. Steadman HJ, Mulvey EP, Monahan J, Robbins PC, Appelbaum PS, Grisso T, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry. 1998;55(5):393–401.
43. Swanson JW, Holzer 3rd CE, Ganju VK, Jono RT. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatr. 1990;41(7):761–70.
44. Tidey JW, Ries RK. People with mental illness. In: Higgins ST, Silverman K, Heil SH, editors. Contingency management in substance abuse treatment. New York: Guilford Press; 2008. p. 202–21.
45. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology. 2011;217(2):279–87. doi:10.1007/s00213-011-2282-8. Although this is a pilot study, it is a well-designed and well-executed randomized clinical trial employing both contingency management and pharmacotherapy for smoking cessation.
46. Vader AM, Walters ST, Prabhu GC, Houck JM, Field CA. The language of motivational interviewing and feedback: counselor language, client language, and client drinking outcomes. Psychol Addict Behav. 2010;24(2):190–7. doi:10.1037/a0018749.
47. Westra HA, Aviram A, Doell FK. Extending motivational interviewing to the treatment of major mental health problems: current directions and evidence. Can J Psychiatry. 2011;56(11):643–50. Provides a review of studies utilizing motivational interviewing to address multiple problem behaviors including substance abuse by individuals with a severe mental illness. The authors thoughtfully discuss issues relevant to maintaining the integrity of MI interventions.
48. Xie H, Drake RE, McHugo GJ, Xie L, Mohandas A. The 10-year course of remission, abstinence, and recovery in dual diagnosis. J Subst Abus Treat. 2010;39(2):132–40. doi:10.1016/j.jsat.2010.05.011.
49. Xie H, McHugo G, Drake R, Sengupta A. Using discrete-time survival analysis to examine patterns of remission from substance use disorder among persons with severe mental illness. Ment Health Serv Res. 2003;5(1):55–64. doi:10.1023/A:1021759509176.